

Annual Evaluation and Performance Measurement Report (I.13- ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) OF INVASIVE *HAEMOPHILUS INFLUENZAE* (*H. INFLUENZAE*) IN JURISDICTION)

Annually, each funded laboratory is required to report to CDC evaluation and performance measures. Data are used to indicate progress made toward program outcomes. These summary reports have to be uploaded to the ELC CAMP at the end of each funding year. Required performance measures are listed below.

| | |
|--|---|
| 1. Susceptibility of invasive <i>H. influenzae</i> (HI) isolates using broth microdilution, according to the Clinical & Laboratory Standards Institute (CLSI) guidelines for at least the following 12 antibiotics with QC-passed broth microdilution test results: | |
| Antibiotic: | Total Number (N) of <i>H. influenzae</i> Isolates with QC-passed broth microdilution |
| 1. Rifampin | |
| 2. Ampicillin | |
| 3. Amoxicillin-clavulanate | |
| 4. Chloramphenicol | |
| 5. Cefotaxime | |
| 6. Ceftriaxone | |
| 7. Cefuroxime | |
| 8. Clarithromycin | |
| 9. Levofloxacin | |
| 10. Meropenem | |
| 11. Tetracycline | |
| 12. Trimethoprim-sulfamethoxazole | |
| 2. Proportion of isolates with AST results reported to CDC-Bacterial Meningitis Laboratory (CDC-BML) yearly: a. Numerator: Number of isolates with AST results reported to CDC yearly b. Denominator: Number of HI isolates received for testing at AR Lab Network c. Calculated: Percentage of isolates with AST results reported to CDC yearly | |
| 3. Number of isolates with AST results reported to CDC-Bacterial Meningitis Laboratory (CDC-BML) yearly (out of up to 500) | |
| 4. Proportion of isolates transported to CDC-BML yearly : a. Numerator: Number of viable isolates transported to CDC or in CDC possession b. Denominator: Total number of HI isolates tested at AR Lab Network c. Calculated: Percent of isolates transported to CDC yearly | |

Public reporting burden of this collection of information is estimated to average **10** minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA 0920-1310